Indocyanine green versus technetium‐99m with blue dye for sentinel lymph node detection in early‐stage cervical cancer: A systematic review and meta‐analysis

Cancer Reports

Ilse G. T. Baeten¹  Ronald P. Zweemer¹  Jacob P. Hoogendam¹  Cornelis G. Gerestein¹  Geertruida N. Jonges²  Arthur J. A. T. Braat³  Wouter B. Veldhuis³  Ina M. Jürgenliemk‐Schulz⁴  Bernadette Jeremiasse⁵  Carla H. vanGils⁶ 

[1] Department of Gynecologic Oncology, Division of Imaging and Oncology University Medical Center Utrecht, Utrecht University Utrecht The Netherlands;Department of Pathology, Division of Laboratory, Pharmacy and Biomedical Genetics University Medical Center Utrecht, Utrecht University Utrecht The Netherlands;Department of Radiology and Nuclear Medicine, Division of Imaging and Oncology University Medical Center Utrecht, Utrecht University Utrecht The Netherlands;Department of Radiotherapy, Division of Imaging and Oncology University Medical Center Utrecht, Utrecht University Utrecht The Netherlands;Department of Surgery Princess Máxima Center for Pediatric Oncology Utrecht The Netherlands;Julius Center for Health Sciences and Primary Care University Medical Center Utrecht, Utrecht University Utrecht The Netherlands;

关键词: cervical cancer;    indocyanine green;    meta‐analysis;    sentinel lymph node;    technetium‐99 m nanocolloid;   

DOI  :  10.1002/cnr2.1401

来源: DOAJ

【 摘 要 】

Abstract Background The fluorescent dye indocyanine green (ICG) has emerged as a promising tracer for intraoperative detection of sentinel lymph nodes (SLNs) in early‐stage cervical cancer. Although researchers suggest the SLN detection of ICG is equal to the more conventional combined approach of a radiotracer and blue dye, no consensus has been reached. Aims We aimed to assess the differences in overall and bilateral SLN detection rates with ICG versus the combined approach, the radiotracer technetium‐99m (99mTc) with blue dye. Methods and Results We searched MEDLINE, Embase, and the Cochrane Library from inception to January 1, 2020 and included studies reporting on a comparison of SLN detection with ICG versus 99mTc with blue dye in early‐stage cervical cancer. The overall and bilateral detection rates were pooled with random‐effects meta‐analyses. From 118 studies retrieved seven studies (one cross‐sectional; six retrospective cohorts) were included, encompassing 589 patients. No significant differences were found in the pooled overall SLN detection rate of ICG versus 99mTc with blue dye. Meta‐analyses of all studies showed ICG to result in a higher bilateral SLN detection rate than 99mTc with blue dye; 90.3% (95%CI, 79.8‐100.0%) with ICG versus 73.5% (95%CI, 66.4‐80.6%) with 99mTc with blue dye. This resulted in a significant and clinically relevant risk difference of 16.6% (95%CI, 5.3‐28.0%). With sensitivity analysis, the risk difference of the bilateral detection rate maintained in favor of ICG but was no longer significant (13.2%, 95%CI −0.8‐27.3%). Conclusion ICG appears to provide higher bilateral SLN detection rates compared to 99mTc with blue dye in patients with early‐stage cervical cancer. However, in adherence with the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines, the quality of evidence is too low to provide strong recommendations and directly omit the combined approach of 99mTc with blue dye.

【 授权许可】

Unknown